Question 1

What are the most cited papers from Empros Pharma (Sweden)?

Accepted Answer

The most cited paper from Empros Pharma (Sweden) is "Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity" (Ulf C. Holmbäck, Anders H. Forslund, Stefan Grudén et al., 2020), with 35 citations. Next come "Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial" (25) and "Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study" (12).

Question 2

Which research topics does Empros Pharma (Sweden) publish most on?

Accepted Answer

By volume in 2022-now: Pharmacology and Obesity Treatment, Bariatric Surgery and Outcomes, Nuts composition and effects and Hormonal and reproductive studies.

Question 3

Which fields of science does Empros Pharma (Sweden) work in?

Accepted Answer

In all years, 84% of research at Empros Pharma (Sweden) is in Health Sciences, 12% in Life Sciences. Its largest fields are Medicine (72%), Biochemistry, Genetics and Molecular Biology (12%), Nursing (12%). It does 1.4× the world's share of Health Sciences.

Question 4

Is Empros Pharma (Sweden)'s research output growing?

Accepted Answer

Output in 2022-2025 was 39% lower than in 2018-2021.